The challenge of managing coexistent type 2 diabetes and obesity

Abstract

The presence of obesity with type 2 diabetes increases morbidity and mortality from each condition. Excess adiposity accentuates insulin resistance and complicates the treatment of type 2 diabetes. Glucagon-like peptide 1 receptor agonists promote weight loss, whereas metformin, dipeptidyl peptidase 4 inhibitors, and a glucosidase inhibitors are typically weight neutral. The anabolic effects of increased insulin secretion and action restrict the benefits of treatment in obese patients. New treatments should ideally reduce hyperglycaemia and excess adiposity. Potential new treatments include analogues of intestinal and adipocyte hormones, inhibitors of renal glucose reabsorption and cellular glucocorticoid activation, and activators of cellular energy production.

Publication DOI: https://doi.org/10.1136/bmj.d1996
Divisions: College of Health & Life Sciences
College of Health & Life Sciences > School of Biosciences
College of Health & Life Sciences > Chronic and Communicable Conditions
Additional Information: Creative Commons Attribution Non-Commerical License
Uncontrolled Keywords: bariatric surgery,type 2 diabetes mellitus,humans,hypoglycemic agents,obesity,weight loss,Medicine(all)
Full Text Link: http://www.bmj. ... t/342/bmj.d1996
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
PURE Output Type: Article
Published Date: 2011-12-23
Authors: Bailey, Clifford J. (ORCID Profile 0000-0002-6998-6811)

Download

Export / Share Citation


Statistics

Additional statistics for this record